Speaking to pharmaphorum on a recent flying visit to London from Celgene's European HQ in Boudry, Switzerland, Pätsi laid out the company's plans for the next few years. Three approvals in three ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...